PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
A study to characterize the single-dose and steady-state pharmacokinetics of tofacitinib
Modified Release (MR) formulation as well as to compare the extent of absorption of the MR 11
mg formulation (once daily) to that of the Immediate Release (IR) 5 mg formulation (twice
daily) of tofacitinib in Chinese healthy subjects under fasted conditions.